[{"id":"0e047eba-7fdc-4c6c-becf-f4667bf4c953","acronym":"","url":"https://clinicaltrials.gov/study/NCT06415487","created_at":"2024-05-15T20:33:36.404Z","updated_at":"2024-07-02T16:35:03.643Z","phase":"Phase 1","brief_title":"ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)","source_id_and_acronym":"NCT06415487","lead_sponsor":"Acepodia Biotech, Inc.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • ACE2016"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 12/18/2026","primary_completion_date":" 12/18/2026","study_txt":" Completion: 03/25/2027","study_completion_date":" 03/25/2027","last_update_posted":"2024-05-15"}]